MTCYBP32

Across TCGA pan-cancer cohorts, MTCYBP32 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTCYBP32 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher MTCYBP32 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCYBP32 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

THCA, DLBC, and SKCM are the cancer types where MTCYBP32 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Tertile	III,IV	0.470	0.812	<.001	54	view →
DLBC	OS	Tertile	III,IV	0.172	0.907	<.001	36	view →
SKCM	DFS	Tertile	All	0.267	0.773	<.001	30	view →
LIHC	DFS	Tertile	All	0.111	0.561	<.001	27	view →
LUAD	DFS	Tertile	III,IV	0.265	0.689	.015	18	view →
TGCT	DFS	Tertile	III,IV	0.017	0.923	.021	18	view →
THYM	OS	Tertile	II,III,IV	0.395	0.862	.047	6	view →
LAML	DFS	Median	All	0.549	0.365	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTCYBP32–THCA (OS)

Open the THCA breakdown →